Among rheumatologists, few payment policy topics have garnered as much attention as Medicare’s Merit-based Incentive Payment System (MIPS), the current CMS program that modifies fee-for-service payments based on defined process and outcome measures. MIPS is complex, and its associated data collection and reporting burden disproportionately affects small practices.
As a membership benefit, United Rheumatology offers members complimentary access to our proprietary Qualified Clinical Data Registry — UREQA — to satisfy MIPS requirements and assure appropriate payment for services delivered and results achieved. The United Rheumatology Effectiveness and Quality Analytics (UREQA) registry also offers our members and others the opportunity to report on measures developed by UR’s Medical Policy Committee, and focused on the oft-unique circumstances facing physicians delivering care in community settings.
Reporting Community-Relevant Measures
A number of new, rheumatology-specific quality measures are available for MIPS reporting exclusively through UREQA. Nearly 300 existing MIPS quality measures, including eCQMs are also supported.
Integrated with the Data Project
For practices submitting data to United Rheumatology’s data warehouse, the resulting EMR files can be used to satisfy MIPS measures through UREQA, eliminating the need for redundant submission to a separate registry.
All MIPS Categories Supported
In addition to submitting quality data, participants can use UREQA to attest for Advancing Care Information (ACI) and Clinical Practice Improvement Activities (CPIA).
Flexible Data Submission
UREQA accepts multiple methods of data entry for members that require additional flexibility due to EMR constraints.
Know Where You Stand
Participants can access a personalized, web-based dashboard that summarizes MIPS performance, estimates scoring, and illuminates improvement opportunities.
Free For Members
UREQA is included as a benefit of United Rheumatology membership, in support of our mission to improve the independent practice of rheumatology.
UREQA and UREQA QCDR measures have been approved by CMS for MIPS reporting in 2018. Additional measures have been proposed for 2019.
If you have questions or would like to participate, please contact your Member Solutions Representative, or contact UREQAsupport@unitedrheumatology.com.